Nvidia Enters CPU Market, Challenging AMD and Intel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: NASDAQ.COM
- Market Share Growth: Nvidia anticipates that its Vera server CPUs will drive $20 billion in revenue this fiscal year, indicating strong demand that could threaten AMD and Intel's market dominance.
- New Product Launch: Nvidia has introduced the RTX Spark Superchip aimed at supporting laptops and PCs running Windows, which is expected to attract partnerships with multiple OEMs, further expanding its influence in the client CPU market.
- Architectural Advantage: Nvidia's CPUs are designed using Arm architecture, with projections indicating that Arm-based CPUs could capture 90% of the server market by 2029, providing robust support for Nvidia's expansion in the CPU sector.
- Growth Potential: Market research suggests that the server CPU market could grow at an annual rate of 35% to reach $120 billion by 2030, and Nvidia's entry will intensify competition and drive overall market development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 204.650
Low
200.00
Averages
264.97
High
352.00
Current: 204.650
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is an artificial intelligence (AI) infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. Its segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing and networking platforms and AI solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment includes GeForce GPUs for gaming and personal computers (PCs), and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. Its technology stack includes the foundational NVIDIA CUDA development platform that runs on all NVIDIA GPUs, as well as hundreds of domain-specific software libraries, frameworks, algorithms, software development kits (SDKs), and application programming interfaces (APIs). Its platforms address four markets, which include Data Center, Gaming, Professional Visualization, and Automotive.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon's Cloud Services Accelerate Growth Amid Market Volatility
- Cloud Revenue Growth: Amazon's first-quarter AWS revenue rose 28% year-over-year to $37.6 billion, marking its fastest growth in 15 quarters, indicating strong competitive positioning in the cloud market and expected to further boost overall company performance.
- AI-Driven Profit Enhancement: AWS's AI revenue has reached an annual run rate of $15 billion, with a backlog of $364 billion, demonstrating that investments in artificial intelligence are significantly enhancing profitability and driving overall operating margin to a record 13.1%.
- Capital Expenditure Plans: Amazon plans to invest approximately $200 billion by 2026, with $43.2 billion spent in the first quarter primarily on AWS and AI expansion, which has led to a substantial decline in free cash flow, yet management views this as a necessary investment to seize market opportunities.
- In-House Chip Design Advantage: Amazon's custom chips now run at an annual revenue rate exceeding $20 billion, up nearly 40% from the previous quarter, allowing the company to reduce reliance on external suppliers, which is expected to save tens of billions in capital expenditures while enhancing AWS's margins.
See More
Nvidia's Stock Surge and Dividend Analysis
- Outstanding Stock Performance: As of June 17, Nvidia's shares have surged 1,050% over the past five years, highlighting its strong position in the AI boom and attracting significant investor interest.
- Dividend Increase: In May, Nvidia raised its quarterly dividend from $0.01 to $0.25 per share, yet investors need to own 10,000 shares to generate $10,000 in annual income, indicating limited appeal for income-focused investors.
- High Investment Cost: At the current price of $206.45, investors would need to spend nearly $2.1 million to acquire enough shares for passive income, making it unattractive for those seeking stable cash flow.
- Low Dividend Yield: With a dividend yield of only 0.48%, significantly below the S&P 500 average of 1.04%, Nvidia is better suited for growth investors looking for capital appreciation rather than dividend income.
See More
Software Companies Embrace AI Opportunities
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, providing a positive signal for the software sector and potentially prompting investors to revisit undervalued stocks.
- Veeva Systems Strong Growth: Veeva Systems reported a 16% year-over-year revenue increase in Q1 FY2027, reaching $882.9 million, with adjusted EPS at $2.24, highlighting strong market demand and customer loyalty in the life sciences sector.
- Adobe's Solid Financial Performance: Adobe's revenue grew 13% year-over-year in Q2 FY2026 to a record $6.62 billion, with adjusted EPS at $5.96, demonstrating the company's continued leadership in digital content creation despite market challenges.
- AI Tools Driving Innovation: Adobe's AI innovations have led to a threefold increase in annual recurring revenue to over $500 million, indicating the company's potential to leverage AI for enhancing products and services, further solidifying its competitive advantage.
See More
Software Companies Set to Benefit from AI Technology
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, creating new investment opportunities for the software sector amid current market downturns.
- Veeva Systems Growth: In Q1 of fiscal year 2027, Veeva Systems reported a 16% year-over-year revenue increase to $882.9 million, with adjusted EPS at $2.24, reflecting strong performance and demand in the life sciences sector.
- Adobe's Financial Stability: Adobe's revenue in Q2 of fiscal year 2026 rose 13% year-over-year to a record $6.62 billion, with adjusted EPS at $5.96, indicating robust fundamentals despite leadership changes affecting its stock performance.
- Impact of AI Tools: Adobe's AI innovations have driven a threefold increase in annual recurring revenue to over $500 million, demonstrating that ongoing investments in AI will support long-term growth and enhance its competitive position in the market.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Market Leadership: Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis (CF) drug market, while Eli Lilly excels in anti-obesity medications and diabetes care, although both companies are actively seeking to reduce their reliance on their core markets.
- Non-Opioid Drug Innovation: Vertex's Journavx became the first oral non-opioid pain signal inhibitor approved by the FDA, and while it has not generated significant revenue yet, sales are expected to ramp up over the next few years, helping the company decrease its dependence on CF products.
- Acquisition Strategy: Eli Lilly acquired SiteOne Therapeutics last year for up to $1 billion, securing the key asset STC-004, a non-opioid treatment for chronic pain, and recently announced the acquisition of 4E Therapeutics, further expanding its footprint in the non-opioid pain treatment space.
- Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, providing both Vertex and Eli Lilly with significant profit potential in this market; despite Vertex's first-mover advantage, Eli Lilly could still dominate if its candidates demonstrate superior efficacy.
See More
Cardano's Dim Prospects Highlighted by Failed Governance Vote
- Governance Vote Failure: The Cardano community's vote to allocate 7.8 million ADA for the 2026 Summit in Singapore failed with only 65.2% support, falling short of the 66.6% supermajority, indicating governance standards may be too high and hindering ecosystem development.
- Ecosystem Risks: The founder warned of an impending 'wave of ecosystem failures' and went silent for several days in early June, reflecting Cardano's vulnerable position compared to competitors like Ethereum and Solana, which could lead to diminished investor confidence.
- Tokenomics Issues: Cardano does not burn transaction fees or conduct token buybacks, meaning holders receive no additional returns from network activity, and staking yields primarily come from newly issued reserves, exposing holders to inflation risks.
- Declining Investment Appeal: While holding Cardano tokens allows for governance participation, the actual returns are limited, and analysts suggest Cardano is not among the best stocks to invest in currently, indicating insufficient long-term growth potential.
See More
Amazon's Cloud Services Accelerate Growth Amid Market Volatility
- Cloud Revenue Growth: Amazon's first-quarter AWS revenue rose 28% year-over-year to $37.6 billion, marking its fastest growth in 15 quarters, indicating strong competitive positioning in the cloud market and expected to further boost overall company performance.
- AI-Driven Profit Enhancement: AWS's AI revenue has reached an annual run rate of $15 billion, with a backlog of $364 billion, demonstrating that investments in artificial intelligence are significantly enhancing profitability and driving overall operating margin to a record 13.1%.
- Capital Expenditure Plans: Amazon plans to invest approximately $200 billion by 2026, with $43.2 billion spent in the first quarter primarily on AWS and AI expansion, which has led to a substantial decline in free cash flow, yet management views this as a necessary investment to seize market opportunities.
- In-House Chip Design Advantage: Amazon's custom chips now run at an annual revenue rate exceeding $20 billion, up nearly 40% from the previous quarter, allowing the company to reduce reliance on external suppliers, which is expected to save tens of billions in capital expenditures while enhancing AWS's margins.
See More
Nvidia's Stock Surge and Dividend Analysis
- Outstanding Stock Performance: As of June 17, Nvidia's shares have surged 1,050% over the past five years, highlighting its strong position in the AI boom and attracting significant investor interest.
- Dividend Increase: In May, Nvidia raised its quarterly dividend from $0.01 to $0.25 per share, yet investors need to own 10,000 shares to generate $10,000 in annual income, indicating limited appeal for income-focused investors.
- High Investment Cost: At the current price of $206.45, investors would need to spend nearly $2.1 million to acquire enough shares for passive income, making it unattractive for those seeking stable cash flow.
- Low Dividend Yield: With a dividend yield of only 0.48%, significantly below the S&P 500 average of 1.04%, Nvidia is better suited for growth investors looking for capital appreciation rather than dividend income.
See More
Software Companies Embrace AI Opportunities
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, providing a positive signal for the software sector and potentially prompting investors to revisit undervalued stocks.
- Veeva Systems Strong Growth: Veeva Systems reported a 16% year-over-year revenue increase in Q1 FY2027, reaching $882.9 million, with adjusted EPS at $2.24, highlighting strong market demand and customer loyalty in the life sciences sector.
- Adobe's Solid Financial Performance: Adobe's revenue grew 13% year-over-year in Q2 FY2026 to a record $6.62 billion, with adjusted EPS at $5.96, demonstrating the company's continued leadership in digital content creation despite market challenges.
- AI Tools Driving Innovation: Adobe's AI innovations have led to a threefold increase in annual recurring revenue to over $500 million, indicating the company's potential to leverage AI for enhancing products and services, further solidifying its competitive advantage.
See More
Software Companies Set to Benefit from AI Technology
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, creating new investment opportunities for the software sector amid current market downturns.
- Veeva Systems Growth: In Q1 of fiscal year 2027, Veeva Systems reported a 16% year-over-year revenue increase to $882.9 million, with adjusted EPS at $2.24, reflecting strong performance and demand in the life sciences sector.
- Adobe's Financial Stability: Adobe's revenue in Q2 of fiscal year 2026 rose 13% year-over-year to a record $6.62 billion, with adjusted EPS at $5.96, indicating robust fundamentals despite leadership changes affecting its stock performance.
- Impact of AI Tools: Adobe's AI innovations have driven a threefold increase in annual recurring revenue to over $500 million, demonstrating that ongoing investments in AI will support long-term growth and enhance its competitive position in the market.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Market Leadership: Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis (CF) drug market, while Eli Lilly excels in anti-obesity medications and diabetes care, although both companies are actively seeking to reduce their reliance on their core markets.
- Non-Opioid Drug Innovation: Vertex's Journavx became the first oral non-opioid pain signal inhibitor approved by the FDA, and while it has not generated significant revenue yet, sales are expected to ramp up over the next few years, helping the company decrease its dependence on CF products.
- Acquisition Strategy: Eli Lilly acquired SiteOne Therapeutics last year for up to $1 billion, securing the key asset STC-004, a non-opioid treatment for chronic pain, and recently announced the acquisition of 4E Therapeutics, further expanding its footprint in the non-opioid pain treatment space.
- Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, providing both Vertex and Eli Lilly with significant profit potential in this market; despite Vertex's first-mover advantage, Eli Lilly could still dominate if its candidates demonstrate superior efficacy.
See More
Cardano's Dim Prospects Highlighted by Failed Governance Vote
- Governance Vote Failure: The Cardano community's vote to allocate 7.8 million ADA for the 2026 Summit in Singapore failed with only 65.2% support, falling short of the 66.6% supermajority, indicating governance standards may be too high and hindering ecosystem development.
- Ecosystem Risks: The founder warned of an impending 'wave of ecosystem failures' and went silent for several days in early June, reflecting Cardano's vulnerable position compared to competitors like Ethereum and Solana, which could lead to diminished investor confidence.
- Tokenomics Issues: Cardano does not burn transaction fees or conduct token buybacks, meaning holders receive no additional returns from network activity, and staking yields primarily come from newly issued reserves, exposing holders to inflation risks.
- Declining Investment Appeal: While holding Cardano tokens allows for governance participation, the actual returns are limited, and analysts suggest Cardano is not among the best stocks to invest in currently, indicating insufficient long-term growth potential.
See More
